ロード中...
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...
保存先:
| 出版年: | BMC Urol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/ https://ncbi.nlm.nih.gov/pubmed/34210300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|